Применение моноклональных антител для лечения коронавирусной инфекции у беременных и родильниц

Abstract

Aim: to compare the efficacy of monoclonal antibodies for novel coronavirus infection treatment in pregnant women. Patients and Methods: a retrospective analysis of medical reports of 502 pregnant and puerperal women aged 18–49 years with mild-to- moderate novel coronavirus infection who received monoclonal antibodies was performed. Women were divided into two groups. Group 1 included 108 women who received sotrovimab. Group 2 included 394 women who received bamlanivimab plus etesevimab. The condition was evaluated over 14 days after administering drug(s) based on the data of the general condition survey and laboratory and instrumental tests on days 1, 3, and 7 of follow-up. Lung damage was detected using ultrasound. Results: the maximum number of patients with lung damage grades 1a and 2a was identified on day 3 after starting therapy, i.e., 34.6% in the sotrovimab group and 71.8% in the bamlanivimab plus etesevimab group. On day 14 after starting therapy, most women recovered. When comparing the efficacy of two treatments, sotrovimab was superior to bamlanivimab plus etesevimab (recovery was reported in 96% and 89%, respectively). No adverse events after sotrovimab administration were reported. No therapy-associated clinically significant events were detected using ultrasound during pregnancy and the postnatal period on days 3 and 7 after drug administration. Conclusion: treatment for mild-to-moderate novel coronavirus infection with monoclonal antibodies in pregnant women is effective and reduces the number of hospital admissions, complications, and maternal and perinatal mortality. KEYWORDS: COVID-19, pregnancy, monoclonal antibodies, obstetric risk, efficacy. FOR CITATION: Polikarpova O.V., Dobrokhotova Yu.E., Shevchenko N.A., Grabovskiy V.M., Lysenko M.A. Monoclonal antibodies for coronavirus infection in pregnant and puerperal women. Russian Journal of Woman and Child Health. 2023;6(3):241–246 (in Russ.). DOI: 10.32364/2618-8430-2023-6-3-4